Variable | Axitinib | Sunitinib | Sorafenib | P 1 | P 2 | P 3 |
---|---|---|---|---|---|---|
Maximal diameter (cm)a | ||||||
Before therapy | 7.2 (6.2–8.5) | 6.4 (5.7–10.3) | 6.8 (5.8–11.0) | 0.497 | 0.664 | 0.868 |
After therapy | 5.2 (4.4–7.4) | 5.6 (5.1–9.8) | 6.4 (4.8–6.4) | 0.266 | 0.284 | 0.657 |
Reduction | 1.5 (1.2–2.2) | 0.8 (0.5–1.1) | 0.5 (0.4–0.8) | 0.001 | < 0.001 | 0.024 |
Reduction rate (%)a | 22.4 (13.8–30) | 12.2 (7.1–14.1) | 6.9 (3.7–12.0) | 0.001 | 0.001 | 0.023 |
> 10% reduction [cases (%)] | 13 (86.7) | 16 (66.7) | 8 (26.7) | 0.310* | 0.001* | 0.003* |